Sethi to leave AstraZeneca to take up Oncimmune post

contract
Oncimmune used its release announcing Tariq Sethi’s arrival to share details of two other new hires. (Pixabay)

Tariq Sethi is set to leave AstraZeneca to join Oncimmune as chief scientific officer at the start of next month. Sethi spent the past four years at AstraZeneca, rising to the post of chief physician scientist at its clinical discovery unit.

AstraZeneca hired Sethi in 2015 to work at a translational medicine unit that handled respiratory, immunology and autoimmune programs. Sethi took on the chief physician scientist title two years later, giving him a role in target validation, patient segmentation, asset repurposing and a search for drivers of lung cancer.   

Those tasks, notably the search for lung cancer drivers, made use of the experience and networks Sethi accrued in academia. Sethi remains an emeritus professor of respiratory medicine at King’s College London and worked at the academic center and the University of Edinburgh for years before joining AstraZeneca.

Webinar

CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

The AstraZeneca appointment moved Sethi into industry, but the physician scientist already had some exposure to the field through his involvement in Galecto Biotech, a Danish biotech. Galecto set up shop around the start of the decade to build on Sethi’s research into galectin-3.

Based on that résumé, Oncimmune said Sethi is “very well placed to direct and lead [its] discovery research, translational and clinical programs effectively” in a statement to disclose the new hire. 

Oncimmune used the release about Sethi’s arrival to share details of two other new hires. Matthew Luttrell is set to join Oncimmune as chief commercial officer. Luttrell joins from Takeda, where he spent eight months following the acquisition of his former employer—Shire—managing the portfolio of hematology products in emerging markets. Earlier in his career, Luttrell worked at drug companies including Eli Lilly, Gilead, GlaxoSmithKline and Novo Nordisk.

Luttrell and Sethi will arrive at a company that recently installed a new head of investor relations. Cléa Rosenfeld, formerly of Shire, took up the position in July. 

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

The FDA approved its first rapid in vitro diagnostic for confirming Ebola virus infections with potential results in about a half-hour.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.